Sick Economics

Searching For Healthy Profits In The Stock Market


Alzheimer's Biotech Stocks

The past few days have been trying times for the global Alzheimer’s community. Biogen and Eisai Inc were forced to halt a stage 3 trial of a formerly promising compound when it became clear that the treatment, named Aducanumab, wouldn’t come close to meeting study endpoints. After much anticipation, it became clear that Aducanumab just doesn’t work. In just a few days, billions of dollar in R&D investment and badly needed revenue potential vanished into thin air.  But hope persists. Here are four biotechs that are forging ahead with novel approaches to the dreaded disease.


It’s not how many times you get knocked down that counts, but how many times you get back up.”  

-General George Custer


1) Neurotrope, Inc. ($NTRP)

Rather than treating amyloid plaques directly, this scrappy startup is targeting another hallmark of demented patients; weakened or erased synaptic connections between brain cells.  Think of Neurotrope as an electrician working to strengthen the electrical grid in a complex building.

$NTRP is moving forward with testing of it’s patented Bryostatin-1, an agent originally derived from jellyfish. One key advantage for Bryostatin-1 is that it has been studied in cancer patients for years, thus there are no fears of toxicity in humans. Neurotrope has successfully regrown brain wiring in mice, and already shown some tantalizing  human results in a preliminary phase 2 study. A much larger phase 2 study is currently underway, with a readout expected before the end of 2019.




2) Denali Therapeutics, Inc. ($DNLI)

The scientists at Denali believe that many of the negative symptoms of Alzheimer’s are results of bad inflammation in the brain. Specifically, they are targeting a protein in the brain called RIPK1 that drives unhealthy inflammation. In mouse models, Denali has produced dramatic benefits by dialing down the effects of the RIPK1 protein. Can this same benefit be delivered in human test subjects?  Denali describes it’s work with this drug candidate as “early clinical.” That is Pharma speak for “we shall see…”


3) Alector, Inc ($ALEC)

Alector was founded under the hypothesis that the immune system is a key driver of brain health. Thus, Alzheimer’s and other neuro maladies can be prevented or cured by modulating the immune system’s actions in the brain. $ALEC has two early stage drug candidates it is developing in partnership with Abbvie. If the Alector scientific team is proven correct, it would be nothing less than a revolution in our understanding of the human brain.


4) Biogen and Eisai ($BIIB) & ($ESALY)

Are you reading this correctly? Yes, you are.  Fresh after enduring a stock market plunge that erased billions in shareholder wealth, the “dynamic duo” are at it again.  The failure of Aducanumab has fueled a lot of speculation that the “amyloid plaque” hypothesis of Alzheimer’s is wrong. So many different drugs have been designed to prevent or remove amyloid plaques from the brain; all have failed to improve or prevent dementia in real world patients.

Now Biogen and Eisai are moving forward with yet another candidate that relies upon the Amyloid Hypothesis. Within hours of announcing the discontinuation of the aducanaub program, they announced a new phase three trial for BAN2401, a different agent that has been in development. Incredibly resilient?  Or incredibly foolish? You be the judge.


Anyone who chooses to invest their hard earned capital in any of these companies must understand that the odds of success are long. Many billions of dollars have been lost in the quest to cure Alzheimer’s disease. Many scientific careers have died an ugly death on crushed hopes. Yet anyone who has experienced first hand the utter devastation caused by this cruel disease knows that we must continue to take these risks. A better world depends on us.


DISCLOSURE: the Sick Economist owns shares in $NTRP


Subscribe To Our Newsletter And Get Your Free E-Book

sick economics

You understand that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person. You further understand that none of the bloggers, information providers, app providers, or their affiliates are advising you personally concerning the nature, potential, value or suitability of any particular security, portfolio of securities, transaction, investment strategy or other matter. To the extent that any of the content published on the Site may be deemed to be investment advice or recommendations in connection with a particular security, such information is impersonal and not tailored to the investment needs of any specific person. You understand that an investment in any security is subject to a number of risks, and that discussions of any security published on the Site will not contain a list or description of relevant risk factors.

The Site is not intended to provide tax, legal, insurance or investment advice, and nothing on the Site should be construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security by Sick Economics or any third party. You alone are solely responsible for determining whether any investment, security or strategy, or any other product or service, is appropriate or suitable for you based on your investment objectives and personal and financial situation. You should consult an attorney or tax professional regarding your specific legal or tax situation.